The STORM trial and beyond: narrowing the horizon of adjuvant sorafenib for postoperative hepatocellular carcinoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. Sorafenib improves lipiodol deposition in transarterial chemoembolization of Chinese patients with hepatocellular carcinoma: a long-term, retrospective study.Oncotarget · 2017
   Article
2. Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017
   Article
3. New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.Journal of clinical and translational hepatology · 2017
   Review
4. Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges.Oncotarget · 2017
   Review
5. Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: A real-world study.Oncotarget · 2017
   Article
6. Harms and benefits of adoptive immunotherapy for postoperative hepatocellular carcinoma: an updated review.Oncotarget · 2017
   Review
7. Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients.Journal of hepatocellular carcinoma · 2017
   Article
8. Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial.World journal of hepatology · 2016
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as